Lexis+ with Protégé vs Causaly (2026)

Lexis+ with Protégé

by LexisNexis

Causaly

by Causaly

Pros

• ✓Outputs grounded in 161M+ verified legal documents with Shepard Citations validation means verifiable legal citations with status and treatment signals rather than potential AI hallucinations, critical given the surge of AI hallucination sanctions against attorneys in 2026.
• ✓Protege Work orchestrates multi-step legal tasks through structured plans with visibility and control at each stage, while 300+ pre-built workflows plus a no-code Custom Workflow Builder reduce setup time compared to building legal AI playbooks from scratch.
• ✓Deepest integration stack among legal AI platforms: Microsoft 365 (6 apps), iManage, SharePoint, OpenText, Google Drive, plus multi-model support (Anthropic, OpenAI, Microsoft, AWS, Mistral) means AI works inside existing legal workflows rather than requiring tool switching.

Limitations

• ⚠Custom pricing without published reference rates makes budgeting harder than tools with public pricing: firms must contact LexisNexis sales, and the Forrester TEI studies provide ROI frameworks but not specific subscription costs for comparison.
• ⚠Most valuable when bundled with existing LexisNexis subscriptions: standalone value depends on content licenses, and firms already committed to Westlaw may find CoCounsel ($428/month bundled with Westlaw, 75 G2 reviews at 4.8) a more natural fit for their existing ecosystem.
• ⚠G2 shows only 2 reviews under the former Lexis+ AI name following the February 2026 rebrand: procurement teams relying on G2 for vendor evaluation will find thin public review evidence relative to the actual scale of deployment across Am Law 50 firms and major law schools.

Pros

• ✓Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
• ✓Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
• ✓Agentic AI agents purpose-built for pharmaceutical R&D use cases including target identification, drug repositioning, mechanism of action investigation, and safety assessment produce outputs with traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

• ⚠Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
• ⚠Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
• ⚠Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/month) or ChatGPT Deep Research ($20/month) substantially more cost-effective outside pharma R&D workflows.